JP2017533707A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533707A5
JP2017533707A5 JP2017523289A JP2017523289A JP2017533707A5 JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5 JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017523289 A JP2017523289 A JP 2017523289A JP 2017533707 A5 JP2017533707 A5 JP 2017533707A5
Authority
JP
Japan
Prior art keywords
cells
population
cancer
disease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533707A (ja
JP6884697B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058228 external-priority patent/WO2016069993A1/en
Publication of JP2017533707A publication Critical patent/JP2017533707A/ja
Publication of JP2017533707A5 publication Critical patent/JP2017533707A5/ja
Application granted granted Critical
Publication of JP6884697B2 publication Critical patent/JP6884697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523289A 2014-10-31 2015-10-30 T細胞を刺激および拡大する組成物および方法 Active JP6884697B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073268P 2014-10-31 2014-10-31
US62/073,268 2014-10-31
PCT/US2015/058228 WO2016069993A1 (en) 2014-10-31 2015-10-30 Compositions and methods of stimulating and expanding t cells

Publications (3)

Publication Number Publication Date
JP2017533707A JP2017533707A (ja) 2017-11-16
JP2017533707A5 true JP2017533707A5 (enExample) 2018-12-06
JP6884697B2 JP6884697B2 (ja) 2021-06-09

Family

ID=55858377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523289A Active JP6884697B2 (ja) 2014-10-31 2015-10-30 T細胞を刺激および拡大する組成物および方法

Country Status (9)

Country Link
US (2) US11471487B2 (enExample)
EP (1) EP3217989B1 (enExample)
JP (1) JP6884697B2 (enExample)
KR (2) KR102583138B1 (enExample)
CN (1) CN107106609A (enExample)
AU (1) AU2015339106B2 (enExample)
CA (1) CA2966035A1 (enExample)
ES (1) ES2910227T3 (enExample)
WO (1) WO2016069993A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234479B2 (en) 2016-12-30 2025-02-25 Cytocares (Shanghai) Inc. Bifunctional molecule and use thereof
US11535666B2 (en) 2016-12-30 2022-12-27 Cytocares (Shanghai) Inc. Trifunctional molecule and application thereof
JP7039623B2 (ja) * 2017-05-26 2022-03-22 グリーン・クロス・ラブ・セル・コーポレイション 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法
CA3248436A1 (en) 2017-09-01 2025-02-21 Lonza Walkersville, Inc. END-TO-END AUTOMATION OF CELL THERAPY
JP7396777B2 (ja) 2018-09-28 2023-12-12 オクタン バイオテック インコーポレーテッド 磁気分離
AU2019381526B2 (en) 2018-11-14 2023-02-23 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells
JP7477091B2 (ja) 2018-12-21 2024-05-01 オクタン バイオテック インコーポレーテッド モジュラー生物製剤生産ユニットのためのカルーセル
CA3123449A1 (en) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
CN113498432A (zh) 2019-02-08 2021-10-12 隆萨沃克斯维尔股份有限公司 用于自动化生物反应器的细胞浓缩方法和装置
IL292409A (en) 2019-10-24 2022-06-01 Octane Biotech Inc A cell culture chamber with enhanced cell contact surfaces
KR20220097457A (ko) 2019-11-11 2022-07-07 론자 워커스빌 아이엔씨. 자동화된 세포 처리를 위한 품질 관리 방법
KR20220128988A (ko) * 2019-11-27 2022-09-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-cd3 scfv 및 사이토카인 생산용 인공 항원 제시 세포
CN114606263B (zh) * 2022-05-11 2022-09-06 上海优替济生生物医药有限公司 分离的核酸分子及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
DE69433970T2 (de) 1993-08-10 2005-08-11 W.L. Gore & Associates, Inc., Newark Zelleinkapselungsvorrichtung
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
CA2401327C (en) 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
WO2005118788A2 (en) * 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130164272A1 (en) * 2010-08-18 2013-06-27 Udai S. Kammula Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
JP6389166B2 (ja) * 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗b7−h6抗体、融合タンパク質、及びこれらを使用する方法
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP2017533707A5 (enExample)
JP2017535261A5 (enExample)
JP2017533706A5 (enExample)
JP2021058196A5 (enExample)
Zhang et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Bi et al. NK cell exhaustion
Moscarelli et al. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells
JP2018504910A5 (enExample)
ES3023783T3 (en) Engineered gamma delta t-cells
Wang et al. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges
MX2023001962A (es) Composiciones anti-cd28.
JP2018533625A5 (enExample)
MX2022012409A (es) Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores.
JP2019532625A5 (enExample)
JP2019500894A5 (enExample)
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2014533928A5 (enExample)
FI3102609T3 (fi) Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi
JP2016539929A5 (enExample)
CN118421557A (zh) 选择性扩增γδT细胞群的方法及其组合物
JP2018500006A5 (enExample)
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
WO2015123642A1 (en) Chimeric antigen receptors and methods of making
JP2016520074A5 (enExample)
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs